Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2020 Filed Apr 2, 2020 20:16 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Tax withholdingCommon Stock | 40,090 | $234.01 | $9,381,460.90 |
DisclosureSEC source: 0001209191-20-022539 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,491 Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:29 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 480 | $238.33 | $114,398.40 |
DisclosureSEC source: 0001209191-20-013016 · doc4.xml · nonDerivative · entry 8 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,902 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $238.33 (range $238.16 to $238.54). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:29 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 160 | $236.80 | $37,888.00 |
DisclosureSEC source: 0001209191-20-013016 · doc4.xml · nonDerivative · entry 7 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,382 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:29 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 280 | $235.53 | $65,948.40 |
DisclosureSEC source: 0001209191-20-013016 · doc4.xml · nonDerivative · entry 6 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,542 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $235.53 (range $235.43 to $235.72). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:29 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 574 | $234.52 | $134,614.48 |
DisclosureSEC source: 0001209191-20-013016 · doc4.xml · nonDerivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,822 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $234.52 (range $234.22 to $234.82). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:29 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 400 | $232.51 | $93,004.00 |
DisclosureSEC source: 0001209191-20-013016 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,396 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $232.51 (range $232.33 to $233.04). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:29 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 400 | $230.77 | $92,308.00 |
DisclosureSEC source: 0001209191-20-013016 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,796 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $230.77 (range $230.29 to $231.27). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:29 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 734 | $229.72 | $168,614.48 |
DisclosureSEC source: 0001209191-20-013016 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,196 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $229.72 (range $229.23 to $230.14). F3 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:30 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 632 | $238.33 | $150,624.56 |
DisclosureSEC source: 0001209191-20-013020 · doc4.xml · nonDerivative · entry 9 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,179 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $238.33 (range $237.98 to $238.54). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:30 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 20 | $236.88 | $4,737.60 |
DisclosureSEC source: 0001209191-20-013020 · doc4.xml · nonDerivative · entry 8 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,811 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:30 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 420 | $236.36 | $99,271.20 |
DisclosureSEC source: 0001209191-20-013020 · doc4.xml · nonDerivative · entry 7 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,831 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $236.36 (range $235.69 to $236.65). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:30 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 540 | $235.14 | $126,975.60 |
DisclosureSEC source: 0001209191-20-013020 · doc4.xml · nonDerivative · entry 6 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,251 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $235.14 (range $234.61 to $235.56). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:30 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 420 | $234.08 | $98,313.60 |
DisclosureSEC source: 0001209191-20-013020 · doc4.xml · nonDerivative · entry 5 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,791 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $234.08 (range $233.57 to $234.44). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:30 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 360 | $232.35 | $83,646.00 |
DisclosureSEC source: 0001209191-20-013020 · doc4.xml · nonDerivative · entry 4 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,211 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $232.35 (range $232.03 to $232.72). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:30 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 432 | $230.85 | $99,727.20 |
DisclosureSEC source: 0001209191-20-013020 · doc4.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,571 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $230.85 (range $230.51 to $231.30). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:30 UTC |
Arbuckle Stuart AEVP, Chief Commercial Officer
|
SaleCommon Stock | 810 | $229.78 | $186,121.80 |
DisclosureSEC source: 0001209191-20-013020 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,003 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $229.78 (range $229.21 to $230.14). F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:32 UTC |
Kewalramani ReshmaDirector · EVP and CMO
|
SaleCommon Stock | 111 | $239.13 | $26,543.43 |
DisclosureSEC source: 0001209191-20-013025 · doc4.xml · nonDerivative · entry 9 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,626 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $239.13 (range $239.13 to $239.14). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:32 UTC |
Kewalramani ReshmaDirector · EVP and CMO
|
SaleCommon Stock | 420 | $238.28 | $100,077.60 |
DisclosureSEC source: 0001209191-20-013025 · doc4.xml · nonDerivative · entry 8 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,737 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $238.28 (range $238.01 to $238.54). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:32 UTC |
Kewalramani ReshmaDirector · EVP and CMO
|
SaleCommon Stock | 320 | $236.71 | $75,747.20 |
DisclosureSEC source: 0001209191-20-013025 · doc4.xml · nonDerivative · entry 7 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,157 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $236.71 (range $236.31 to $237.24). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:32 UTC |
Kewalramani ReshmaDirector · EVP and CMO
|
SaleCommon Stock | 340 | $235.36 | $80,022.40 |
DisclosureSEC source: 0001209191-20-013025 · doc4.xml · nonDerivative · entry 6 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,477 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $235.36 (range $235.13 to $235.56). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:32 UTC |
Kewalramani ReshmaDirector · EVP and CMO
|
SaleCommon Stock | 660 | $234.41 | $154,710.60 |
DisclosureSEC source: 0001209191-20-013025 · doc4.xml · nonDerivative · entry 5 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,817 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $234.41 (range $233.90 to $234.80). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:32 UTC |
Kewalramani ReshmaDirector · EVP and CMO
|
SaleCommon Stock | 440 | $232.35 | $102,234.00 |
DisclosureSEC source: 0001209191-20-013025 · doc4.xml · nonDerivative · entry 4 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,477 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $232.35 (range $232.14 to $233.08). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:32 UTC |
Kewalramani ReshmaDirector · EVP and CMO
|
SaleCommon Stock | 450 | $230.88 | $103,896.00 |
DisclosureSEC source: 0001209191-20-013025 · doc4.xml · nonDerivative · entry 3 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,917 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F4 · price: Open market sales reported on this line occurred at a weighted average price of $230.88 (range $230.48 to $231.38). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:32 UTC |
Kewalramani ReshmaDirector · EVP and CMO
|
SaleCommon Stock | 893 | $229.72 | $205,139.96 |
DisclosureSEC source: 0001209191-20-013025 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · Director · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,367 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $229.72 (range $229.23 to $230.17). F3 · price: Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:34 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 1,680 | $238.33 | $400,394.40 |
DisclosureSEC source: 0001209191-20-013029 · doc4.xml · nonDerivative · entry 9 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,581 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $238.33 (range $238.16 to $238.56). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:34 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 560 | $236.63 | $132,512.80 |
DisclosureSEC source: 0001209191-20-013029 · doc4.xml · nonDerivative · entry 8 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,261 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:34 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 1,210 | $235.53 | $284,991.30 |
DisclosureSEC source: 0001209191-20-013029 · doc4.xml · nonDerivative · entry 7 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,821 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $235.53 (range $235.07 to $235.72). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:34 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 1,640 | $234.49 | $384,563.60 |
DisclosureSEC source: 0001209191-20-013029 · doc4.xml · nonDerivative · entry 6 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,031 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $234.49 (range $233.99 to $234.66). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:34 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 1,017 | $232.96 | $236,920.32 |
DisclosureSEC source: 0001209191-20-013029 · doc4.xml · nonDerivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,671 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $232.96 (range $232.27 to $233.11). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:34 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 1,050 | $231.76 | $243,348.00 |
DisclosureSEC source: 0001209191-20-013029 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,688 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $231.76 (range $231.27 to $232.14). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:34 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 1,120 | $230.40 | $258,048.00 |
DisclosureSEC source: 0001209191-20-013029 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,738 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $230.40 (range $230.14 to $230.73). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:34 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 2,273 | $229.77 | $522,267.21 |
DisclosureSEC source: 0001209191-20-013029 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,858 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $229.77 (range $229.07 to $230.00). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:35 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 480 | $238.30 | $114,384.00 |
DisclosureSEC source: 0001209191-20-013032 · doc4.xml · nonDerivative · entry 7 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,838 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $238.30 (range $238.16 to $238.54). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:35 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 320 | $236.26 | $75,603.20 |
DisclosureSEC source: 0001209191-20-013032 · doc4.xml · nonDerivative · entry 6 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,318 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $236.26 (range $235.72 to $236.80). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:35 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 640 | $234.77 | $150,252.80 |
DisclosureSEC source: 0001209191-20-013032 · doc4.xml · nonDerivative · entry 5 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,638 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $234.77 (range $234.51 to $235.46). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:35 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 320 | $232.89 | $74,524.80 |
DisclosureSEC source: 0001209191-20-013032 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,278 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $232.89 (range $232.73 to $233.05). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:35 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 330 | $231.62 | $76,434.60 |
DisclosureSEC source: 0001209191-20-013032 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,598 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $231.62 (range $231.12 to $232.06). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:35 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 938 | $230.07 | $215,805.66 |
DisclosureSEC source: 0001209191-20-013032 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,928 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $230.07 (range $229.75 to $230.57). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:36 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 540 | $238.33 | $128,698.20 |
DisclosureSEC source: 0001209191-20-013034 · doc4.xml · nonDerivative · entry 9 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,915 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $238.33 (range $238.16 to $238.54). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:36 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 180 | $236.63 | $42,593.40 |
DisclosureSEC source: 0001209191-20-013034 · doc4.xml · nonDerivative · entry 8 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,455 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:36 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 360 | $235.75 | $84,870.00 |
DisclosureSEC source: 0001209191-20-013034 · doc4.xml · nonDerivative · entry 7 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,635 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $235.75 (range $235.63 to $235.82). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:36 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 533 | $234.56 | $125,020.48 |
DisclosureSEC source: 0001209191-20-013034 · doc4.xml · nonDerivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,995 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $234.56 (range $234.27 to $234.66). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:36 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 90 | $233.18 | $20,986.20 |
DisclosureSEC source: 0001209191-20-013034 · doc4.xml · nonDerivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,528 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:36 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 450 | $232.62 | $104,679.00 |
DisclosureSEC source: 0001209191-20-013034 · doc4.xml · nonDerivative · entry 4 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,618 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $232.62 (range $232.06 to $233.05). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:36 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 270 | $230.98 | $62,364.60 |
DisclosureSEC source: 0001209191-20-013034 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,068 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $230.98 (range $230.57 to $231.26). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:36 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 953 | $230.00 | $219,190.00 |
DisclosureSEC source: 0001209191-20-013034 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,338 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $230.00 (range $229.52 to $230.31). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:37 UTC |
Silva Paul MSVP & Controller
|
SaleCommon Stock | 150 | $238.40 | $35,760.00 |
DisclosureSEC source: 0001209191-20-013037 · doc4.xml · nonDerivative · entry 8 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,932 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $238.40 (range $238.19 to $238.54). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:37 UTC |
Silva Paul MSVP & Controller
|
SaleCommon Stock | 90 | $236.85 | $21,316.50 |
DisclosureSEC source: 0001209191-20-013037 · doc4.xml · nonDerivative · entry 7 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,082 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $236.85 (range $236.65 to $237.24). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:37 UTC |
Silva Paul MSVP & Controller
|
SaleCommon Stock | 150 | $235.49 | $35,323.50 |
DisclosureSEC source: 0001209191-20-013037 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,172 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $235.49 (range $235.15 to $235.87). Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:37 UTC |
Silva Paul MSVP & Controller
|
SaleCommon Stock | 150 | $234.50 | $35,175.00 |
DisclosureSEC source: 0001209191-20-013037 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,322 F1 · kind: Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $234.50 (range $234.14 to $235.10). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.